Appclon Expands Cancer Drug Candidate’s Potential Beyond Stomach Cancer to Colorectal and Treatment-Resistant Breast Cancer
AI 요약 정보
- Appclon’s AC101 program grows to nine clinical trials
- AC101 Phase 2 targets advanced HER2-positive colorectal cancer
- AC101’s 90-patient Phase 2 targets breast cancer after ADCs